🔍

GKSL - Gujarat Kidney

📊 NSE: GKSL 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

GKSL Shareholders Approve Healthcare Expansion Funds and Financial Statement Revision

🔵 WATCH ⭐ 7/10

REGULATORY 📅 25 Apr 2026, 08:03 PM

Gujarat Kidney and Super Speciality Limited (GKSL) has announced the successful passage of three key resolutions via postal ballot with near-unanimous support. Shareholders approved the interim utilization of funds for healthcare expansion, aligning with the company's IPO objectives. Notably, a special resolution for the voluntary revision of financial statements and the Board's report under Section 131 of the Companies Act was also passed. Additionally, the company confirmed the appointment of Mr. Dharmendra Bhaliya as the Secretarial Auditor for the 2025-26 fiscal year.

Resolution for healthcare expansion fund utilization passed with 100% of 5,68,46,254 valid votes in favor.
Voluntary revision of Financial Statements and Board's Report approved with a 99.9998% majority.
Total voter participation represented 72.10% of the company's total outstanding shares.
Appointment of Mr. Dharmendra Bhaliya as Secretarial Auditor for FY 2025-26 was finalized with 99.9994% approval.

💡 Investors should monitor the specific reasons for the voluntary revision of financial statements to ensure there are no underlying accounting or governance concerns. While the expansion plan is a positive growth indicator, the regulatory revision warrants a cautious approach.

GKSL Fined ₹20,000 by BSE and NSE for SEBI Listing Regulation Non-Compliance

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 16 Apr 2026, 06:43 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has been penalized by both the BSE and NSE for failing to provide timely prior intimation regarding a Board of Directors meeting. The penalty consists of a fine of ₹10,000 plus GST from each exchange, totaling ₹20,000 plus applicable taxes. The company clarified that this non-compliance under Regulation 29 of SEBI (LODR) will not have any material impact on its financial or operational activities. GKSL has committed to paying the fines within the timelines prescribed by the exchanges.

NSE imposed a fine of ₹10,000 plus GST for delay in board meeting intimation.
BSE imposed a matching fine of ₹10,000 plus GST for the same violation.
The violation pertains to Regulation 29(2) and 29(3) of SEBI (LODR) Regulations, 2015.
Management confirms no impact on the company's operations or financial health.

💡 This is a minor administrative lapse with no material impact on the company's fundamentals. Investors should treat this as a routine regulatory update and continue to monitor the company's core operational performance.

GKSL to Close Trading Window from April 1, 2026 for FY26 Audited Financial Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Mar 2026, 02:21 PM

Gujarat Kidney And Super Speciality Limited has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI Insider Trading regulations. This closure precedes the declaration of the company's audited financial results for the fiscal year ending March 31, 2026. The restriction applies to all designated persons, including directors and promoters, preventing them from trading in equity shares. The window will reopen 48 hours after the financial results are officially declared to the exchanges.

Trading window closure begins on Wednesday, April 1, 2026.
Closure is for the purpose of declaring Audited Financial Results for the year ended March 31, 2026.
Restriction applies to all Designated Persons, Directors, Promoters, and their immediate relatives.
The window will remain closed until 48 hours after the results are made public.

💡 This is a routine regulatory filing with no impact on company fundamentals. Investors should wait for the announcement of the board meeting date to review the upcoming annual financial performance.

GKSL to Reallocate ₹3192.5 Lakhs IPO Funds and Revise Past Financial Statements

🔵 WATCH ⭐ 8/10

EXPANSION 📅 25 Mar 2026, 06:14 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has issued a postal ballot seeking shareholder approval to significantly reallocate IPO proceeds. The company plans to divert ₹2510 lakhs originally intended for a Vadodara hospital toward a new multispeciality project in Bharuch and ₹682.50 lakhs toward a dialysis services collaboration. Furthermore, the company is voluntarily revising its financial statements and Board's reports for FY 2021-22, 2022-23, and 2023-24 following an NCLT order to ensure proper disclosure compliance.

Reallocation of ₹3010 lakhs from a proposed Vadodara hospital to a new multispeciality hospital project in Bharuch.
Diversion of ₹682.50 lakhs from robotics equipment to establish dialysis services in collaboration with Lord’s Mark Industries Limited.
Voluntary revision of financial statements and notes for three consecutive years (FY22 to FY24) as per NCLT order dated Feb 6, 2026.
Utilization of ₹1262 lakhs from General Corporate Purposes to fund the revised healthcare expansion objects.
Remote e-voting for these resolutions is scheduled from March 27, 2026, to April 25, 2026.

💡 Investors should closely examine the reasons for the geographic shift in expansion and the implications of the voluntary financial revisions on the company's historical performance data. Monitor the progress of the new Bharuch project as it replaces the original IPO objective.

GKSL Q2 FY26 Results: Revenue Up 2.5% to ₹9.64 Cr, PAT Declines 22% YoY

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 25 Mar 2026, 12:25 PM

Gujarat Kidney And Super Speciality Limited (GKSL) reported a marginal 2.5% YoY revenue growth for Q2 FY26, reaching ₹9.64 crore. However, Profit After Tax (PAT) for the quarter dropped significantly by 22% to ₹2.30 crore compared to the same period last year, indicating margin pressure. On a half-yearly basis, the performance remains positive with revenue up 13% and PAT up 10% YoY. Investors should note a sharp increase in current borrowings to ₹12.71 crore and rising trade receivables, which may impact liquidity.

Q2 Revenue from operations stood at ₹964.26 Lacs, a slight increase from ₹941.00 Lacs YoY.
Quarterly Net Profit declined to ₹230.12 Lacs from ₹295.73 Lacs in the previous year's quarter.
Half-year (H1) PAT grew by 10.1% to ₹620.10 Lacs compared to ₹563.13 Lacs in H1 FY25.
Current borrowings escalated sharply to ₹1,270.71 Lacs from ₹95.53 Lacs in March 2025.
Trade receivables increased to ₹1,862.59 Lacs as of September 2025, up from ₹1,279.91 Lacs in March 2025.

💡 Investors should exercise caution due to the significant rise in short-term debt and trade receivables, which could signal working capital stress. Monitor the company's ability to manage operational costs as quarterly margins have contracted despite stable revenue.

GKSL Acquires Parekhs Hospital Private Limited for ₹77 Crore

🟢 POSITIVE ⭐ 9/10

M&A 📅 23 Mar 2026, 03:19 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has successfully executed the acquisition of a 100% stake in Parekhs Hospital Private Limited for ₹77 crore. The target entity, based in Ahmedabad, is a healthcare service provider with a steady revenue stream, reporting a turnover of ₹25.67 crore in FY 2024-25. This acquisition makes Parekhs Hospital a wholly-owned subsidiary of GKSL, aimed at strengthening the company's presence in the healthcare sector. The transaction was completed on March 22, 2026, through cash consideration.

Acquisition of 100% equity (2,55,000 shares) for a total cash consideration of ₹77 crore
Parekhs Hospital reported a turnover of ₹25.67 crore for FY 2024-25, showing stable performance
Target company has a consistent financial track record with FY 2022-23 turnover at ₹24.06 crore
Strategic expansion into the Ahmedabad healthcare market to diversify GKSL's business portfolio
The acquisition was completed on March 22, 2026, following an initial intimation in January 2026

💡 Investors should view this as a significant growth move, though the acquisition price of ₹77 crore for a ₹25.67 crore turnover business implies a high valuation multiple. Monitor the consolidated financial statements for improvements in margins and operational synergies post-integration.

GKSL Pays Rs 6.6 Lakh Penalty to BSE and NSE for Delayed Financial Results

🔴 NEGATIVE ⭐ 6/10

REGULATORY 📅 21 Mar 2026, 02:17 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has informed the exchanges regarding a penalty payment of Rs 3,30,400 each to BSE and NSE, totaling Rs 6,60,800. The fine was imposed due to the company's failure to submit financial results within the prescribed timelines under Regulation 33 of SEBI LODR Regulations. The notices were received on March 17, 2026, and the company completed the payment via RTGS on March 21, 2026. While the monetary impact is limited, the delay in financial reporting is a negative signal regarding corporate governance and compliance discipline.

Total penalty of Rs 6,60,800 paid to stock exchanges (Rs 3,30,400 each to BSE and NSE).
Penalty triggered by non-compliance with Regulation 33 for delayed submission of financial results.
Notices were issued by the exchanges on March 17, 2026, and received late in the evening.
Company confirmed the full payment of fines was completed on March 21, 2026, via RTGS.

💡 Investors should exercise caution and monitor if the company improves its reporting discipline in future quarters. It is important to review the delayed financial results once published to check for any underlying operational issues.

GKSL Appoints New Auditors; H1 FY26 Revenue Grows to ₹21.09 Cr, PAT at ₹6.20 Cr

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 19 Mar 2026, 09:43 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has appointed Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2025-26 to strengthen corporate governance. The company reported a steady financial performance for the half-year ended September 30, 2025, with revenue from operations reaching ₹2,109.25 Lacs, up from ₹1,867.05 Lacs in the previous year. Net profit for the same period increased to ₹620.10 Lacs compared to ₹563.13 Lacs YoY. Additionally, the board ratified previous meeting outcomes that were delayed in submission to the exchanges.

Revenue from operations grew by 13% YoY to ₹2,109.25 Lacs for the half-year ended September 30, 2025.
Profit After Tax (PAT) for H1 FY26 stood at ₹620.10 Lacs, a growth from ₹563.13 Lacs in H1 FY25.
Total Assets increased significantly to ₹6,694.02 Lacs as of September 2025 from ₹4,907.23 Lacs in March 2025.
Appointment of new Internal and Secretarial Auditors with 7 and 5 years of professional experience respectively.
Current borrowings rose sharply to ₹1,270.71 Lacs from ₹95.53 Lacs in March 2025, indicating potential expansion or working capital needs.

💡 Investors should monitor the company's ability to maintain margins given the rise in current borrowings and other expenses. The steady growth in PAT and strengthening of the audit team are positive signs for long-term governance.

GKSL Appoints New Internal and Secretarial Auditors for FY 2025-26

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 19 Mar 2026, 09:42 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has appointed Mr. Siddharth Atulbhai Shah as Internal Auditor and Mr. Dharmendra Bhaliya as Secretarial Auditor for the 2025-26 financial year. The company also ratified actions from a February 2026 board meeting that were previously not submitted to exchanges due to typographical errors. Financial data included in the filing shows H1 FY26 revenue of ₹2,109.25 Lacs and a Profit After Tax of ₹620.10 Lacs. These appointments are part of the company's annual regulatory compliance cycle.

Appointment of Mr. Siddharth Atulbhai Shah (CA) as Internal Auditor for FY 2025-26.
Appointment of Mr. Dharmendra Bhaliya (CS) as Secretarial Auditor for FY 2025-26.
H1 FY26 Revenue from Operations reported at ₹2,109.25 Lacs, up from ₹1,867.05 Lacs YoY.
H1 FY26 Profit After Tax (PAT) stood at ₹620.10 Lacs compared to ₹563.13 Lacs in the previous year.
Board ratified and confirmed actions from the February 14, 2026, meeting to ensure regulatory compliance.

💡 Investors should view these as routine compliance appointments; however, the steady 10% year-on-year growth in H1 PAT reflects stable operational performance.

GKSL Fined ₹3.30 Lakh by NSE and BSE for Delayed Q2 FY26 Financial Results

🔴 NEGATIVE ⭐ 6/10

REGULATORY 📅 18 Mar 2026, 02:00 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has been penalized by both the National Stock Exchange (NSE) and BSE for non-compliance with SEBI Regulation 33. The exchanges have imposed a fine of ₹3,30,400 due to the company's failure to submit its financial results for the quarter ended September 30, 2025, within the prescribed timeline. While the company claims no significant impact on operations, the delay in reporting is a governance concern. The Board of Directors is expected to review the notice and provide further comments to the exchanges shortly.

NSE and BSE imposed a total fine of ₹3,30,400 including GST for regulatory non-compliance.
The penalty pertains to the non-submission of financial results for the quarter ended September 30, 2025.
Notices from both exchanges were received by the company on March 17, 2026.
The company stated that the fine does not have a quantifiable impact on its financial or operational activities.
The Board of Directors will shortly review the matter and provide official comments to the stock exchanges.

💡 Investors should exercise caution as delays in financial reporting can indicate internal administrative issues or poor corporate governance. Monitor the company's upcoming board comments to understand the reason behind the reporting delay.

GKSL Announces Resignation of Company Secretary and Compliance Officer Niki Paresh Tiwari

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 03 Mar 2026, 01:41 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has informed the exchanges that Mrs. Niki Paresh Tiwari has resigned from her role as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). The resignation was tendered on March 2, 2026, as she intends to pursue career opportunities outside the organization. The company has accepted her resignation and fixed her official relieving date as March 27, 2026. GKSL has already initiated the process of shortlisting potential candidates to fill the vacancy within the timelines prescribed by SEBI regulations.

Mrs. Niki Paresh Tiwari resigned as Company Secretary and Compliance Officer effective March 2, 2026.
The official relieving date for the outgoing KMP has been set for March 27, 2026.
The resignation is attributed to the pursuit of better career opportunities outside the company.
The company is currently in the process of shortlisting candidates to ensure compliance with SEBI (LODR) Regulations regarding KMP appointments.

💡 This is a routine administrative change and does not impact the company's fundamentals. Investors should monitor for the announcement of a new appointment to ensure seamless regulatory compliance.

GKSL Reports Zero Deviation in Utilization of ₹250.80 Crore IPO Proceeds

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 14 Feb 2026, 11:57 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has submitted its statement of deviation for the quarter ended December 31, 2025, confirming that the ₹250.80 crore raised via equity issuance is being handled as per the original objects. The funds were raised on December 24, 2025, and as of the quarter-end, no deviations or variations in utilization were reported. Major allocations include ₹77 crore for the acquisition of Parekhs Hospital and ₹30.10 crore for a new women's hospital in Vadodara. Brickwork Ratings India Private Limited is acting as the monitoring agency for these funds.

Raised a total of ₹250.80 crore through an equity share issue on December 24, 2025.
Reported zero deviation or variation in the use of proceeds for the third quarter of FY26.
Allocated ₹77 crore for the acquisition of Parekhs Hospital Private Limited at Ahmedabad.
Earmarked ₹30.10 crore for capital expenditure for a new women's healthcare hospital in Vadodara.
Allocated ₹87.44 crore for inorganic growth through unidentified acquisitions and general corporate purposes.

💡 Investors should track subsequent quarterly reports to ensure the timely and efficient deployment of funds into the stated acquisition and expansion projects. The successful execution of these capital-intensive projects will be a key driver for the company's long-term growth.

GKSL Receives NCLT Approval for Voluntary Revision of Financials and Board Reports (FY22-FY24)

🟡 NEUTRAL ⭐ 5/10

REGULATORY 📅 14 Feb 2026, 09:21 PM

Gujarat Kidney and Super Speciality Limited (GKSL) has received NCLT approval to voluntarily revise its Board Reports and Financial Statements for three financial years (FY22, FY23, and FY24). The revisions primarily address clerical errors, such as incorrect board meeting dates and director appointment timelines. Crucially, the company is correcting a miscategorization in FY24 where a business transfer amount was wrongly labeled as a 'Loan to directors.' Management has confirmed that these revisions have no impact on the company's financial performance, operations, or other activities.

NCLT Ahmedabad approved the voluntary revision of Board Reports and Financial Statements for FY 2021-22, 2022-23, and 2023-24.
Correction of a miscategorized 'Loan to directors' in FY24 notes, which was actually related to a Business Transfer Agreement.
Rectification of clerical errors regarding the company's conversion date from Private to Public (corrected to 24/11/2023).
The company is directed to pay a nominal fee of ₹10,000 and file revised Form AOC-4 within 30 days.
Management and auditors state there is no quantifiable monetary impact on the company's financial or operational status.

💡 Investors should view this as a corrective governance measure to ensure regulatory accuracy; no immediate action is required as the financials remain fundamentally unchanged. Monitor the filing of the revised reports to confirm the 'Loan to directors' miscategorization is officially resolved.

GKSL Q3 FY26 Standalone PAT Grows 5.4% YoY to ₹2.33 Cr; Revenue Up 14.8%

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 14 Feb 2026, 09:11 PM

Gujarat Kidney And Super Speciality Limited (GKSL) reported a steady performance for the quarter ended December 31, 2025, with standalone revenue from operations rising 14.8% YoY to ₹976.45 Lacs. Net profit for the quarter saw a modest increase to ₹233.26 Lacs from ₹221.20 Lacs in the previous year. For the nine-month period, the company achieved a PAT of ₹853.36 Lacs, representing an 8.8% growth compared to the same period last year. However, bottom-line growth was slightly constrained by a significant jump in finance costs and other operating expenses.

Standalone Revenue from Operations increased to ₹976.45 Lacs in Q3 FY26 from ₹850.64 Lacs in Q3 FY25.
Standalone Profit After Tax (PAT) for the quarter stood at ₹233.26 Lacs, up 5.4% year-on-year.
Nine-month (9M FY26) Standalone PAT reached ₹853.36 Lacs compared to ₹784.42 Lacs in 9M FY25.
Finance costs for the quarter rose sharply to ₹29.22 Lacs from ₹10.68 Lacs in the corresponding quarter last year.
The Board approved consolidated results including subsidiaries Raj Palmland Hospital and Harmony Medicare.

💡 Investors should note the steady revenue growth in the healthcare segment but remain cautious about rising finance costs which may impact margins. The stock's performance will likely depend on the successful integration and contribution of its newly consolidated hospital subsidiaries.

GKSL to Acquire 51% Stake in Patel Pharmacy and Patel Multispeciality Hospital for ₹12.50 Crore

🟢 POSITIVE ⭐ 8/10

M&A 📅 05 Feb 2026, 05:45 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has approved the acquisition of a 51% controlling stake in two entities: Patel Pharmacy and Patel Multispeciality Hospital and ICU. The total cash consideration for these acquisitions is approximately ₹12.50 crore, with ₹3.70 crore allocated for the pharmacy and ₹8.80 crore for the hospital. Both target entities are based in Ankleshwar, Gujarat, and have been operational since 2015. This strategic move is aimed at consolidating GKSL's position in the healthcare sector and diversifying its service portfolio beyond specialized kidney care.

Acquisition of 51% stake in Patel Pharmacy for ₹3.70 crore (FY25 turnover: ₹2.57 crore)
Acquisition of 51% stake in Patel Multispeciality Hospital and ICU for ₹8.80 crore (FY25 turnover: ₹6.46 crore)
Total investment of ₹12.50 crore to be completed via cash consideration within approximately 2 months
Strategic expansion into multispeciality healthcare and pharmacy services to diversify business portfolio
Target entities are established firms in Ankleshwar, Gujarat, with a track record dating back to 2015

💡 Investors should view this as a growth-oriented move that diversifies the company's revenue streams. Monitor the integration of these assets and their contribution to consolidated margins in the next few quarters.

View All GKSL Announcements on Live Market Tracking →

💰 Financial Performance

Financial analysis data not yet available for this company.

⚙️ Operational Drivers

Operational analysis data not yet available for this company.

📈 Strategic Growth

Growth Strategy

The company aims to achieve growth through its positioning as a super-speciality hospital, specifically focusing on kidney care. The strategy involves maintaining NABH accreditation standards to attract patients and potentially expanding service offerings within its Vadodara facility to increase patient throughput and revenue per bed.

Products & Services

Super-speciality healthcare services, nephrology treatments, kidney-related surgeries, and general hospital care services.

Brand Portfolio

Gujarat Kidney and Super Speciality Hospital

Strategic Alliances

The company maintains a relationship with MUFG Intime India Private Limited (formerly Link Intime India Private Limited) for share registry and transfer services.

🌍 External Factors

Industry Trends

The healthcare industry is trending toward specialized care and accreditation-driven quality. GKSL is positioned as an NABH-accredited hospital, which is critical for empanelment with insurance providers and corporate clients, potentially increasing patient volume as the demand for organized healthcare grows in Gujarat.

Competitive Moat

The company's moat is built on its specialized focus on kidney care and its NABH accreditation. This provides a competitive advantage in the Vadodara region by establishing trust and quality benchmarks that are difficult for smaller, unorganized clinics to replicate, ensuring a steady flow of specialized cases.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by healthcare-specific regulations including the Clinical Establishments Act and Bio-Medical Waste Management Rules. Compliance with NABH (National Accreditation Board for Hospitals & Healthcare Providers) standards is maintained to ensure operational quality and safety.

⚠️ Risk Analysis

Geographic Concentration Risk

The company has 100% geographic concentration in Vadodara, Gujarat. This makes the business highly vulnerable to local economic shifts, regional competition, and state-specific healthcare policy changes which could impact patient footfall and revenue.